P324: PHARMACOLOGIC INHIBITION OF DYRK1A RENDERS HIGH-RISK KMT2A-R ALL SENSITIVE TO VENETOCLAX

• C. Hurtz,
• G. Wertheim,
• J. Chukinas,
• R. Bhansali,
• S. Swaminathan,
• J. Crispino,
• J. Shi,
• S. Tasian,
• M. Carroll

Affiliations

C. Hurtz

1 Fels Institute for Personalized Medicine, Temple University

G. Wertheim

2 Department of Pathology and Laboratory Medicine, University of Pennsylvania

J. Chukinas

3 Oncology, CHOP, Philadelphia

R. Bhansali

4 Hematology Oncology, Upenn, Pehiladelphia

S. Swaminathan

5 Systems Biology, City of Hope, Monrovia

J. Crispino

6 Experimental Hematology, St. Jude Children’s Research Hospital, Memphis

J. Shi

7 Cancer Biology

S. Tasian

3 Oncology, CHOP, Philadelphia

M. Carroll

8 Medicine, Upenn, Philadelphia, United States of America